Table 1 Differently Maternal DNA methylation patterns and congenital heart defects
From: The role of DNA methylation in syndromic and non-syndromic congenital heart disease
Study (reference) | Study population Sample type | Cohort | Sample size | Methylation measures | DNA methylation change |
|---|---|---|---|---|---|
[74] | Mothers, Blood | non-syndromic CHD | Case: 180, Control:187 | Methylation of LINE-1 assessed with Methylight was used as a surrogate marker of global DNA methylation status | LINE-1 DNA methylation was significantly lower in cases compared with controls ( P  = 0.049) |
[76] | Mothers, Blood | CHD with Down syndrome | Case: 44, Control: 46 | LINE-1 DNA methylation was analyzed by quantification of LINE-1 methylation using the MethyLight method | LINE-1 methylation was not significantly different between DS-CHD + and DS-CHD − mothers (P = 0.997) |
[77] | Mothers, Blood | non-syndromic CHD | Case: 180, Control:187 | Maternal gene specific methylation in over 27,000 CpG sites was assessed using the Illumina Infinium Human Methylation27 BeadChip | 425 CpG sites encompassing 415 genes were differentially methylated between cases and controls (P < 0.005). The majority of differentially methylated CpG sites were hypermethylated in cases |